139 related articles for article (PubMed ID: 2344368)
1. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
[TBL] [Abstract][Full Text] [Related]
2. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
Skovsgaard T
Cancer Res; 1980 Apr; 40(4):1077-83. PubMed ID: 7357538
[TBL] [Abstract][Full Text] [Related]
4. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.
Sehested M; Skovsgaard T; Roed H
Biochem Pharmacol; 1988 Sep; 37(17):3305-10. PubMed ID: 3401258
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.
Averbuch SD; Clawson RE; Bachur NR; Felsted RL
Cancer Chemother Pharmacol; 1986; 16(3):211-7. PubMed ID: 2421935
[TBL] [Abstract][Full Text] [Related]
6. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
Demant EJ; Sehested M; Jensen PB
Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
[TBL] [Abstract][Full Text] [Related]
7. Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells.
Friche E; Skovsgaard T; Nissen NI
Cancer Chemother Pharmacol; 1987; 19(1):35-9. PubMed ID: 3815723
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Nissen NI
Cancer Chemother Pharmacol; 1992; 30(3):235-7. PubMed ID: 1628375
[TBL] [Abstract][Full Text] [Related]
9. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
[TBL] [Abstract][Full Text] [Related]
10. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
[TBL] [Abstract][Full Text] [Related]
11. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
12. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
13. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
[TBL] [Abstract][Full Text] [Related]
14. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
16. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding.
Broxterman HJ; Kuiper CM; Schuurhuis GJ; van der Hoeven JJ; Pinedo HM; Lankelma J
Cancer Lett; 1987 Apr; 35(1):87-95. PubMed ID: 3471315
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
Friche E; Danks MK; Beck WT
Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
20. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
